You are here: Home Published Research Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I/II randomized clinical study.

Geert Leroux-Roels, Cathy Maes, Fien De Boever, Magali Traskine, Jens U R├╝ggeberg, and Dorota Borys (2014)

Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I/II randomized clinical study.

Vaccine, 32(50):6838–6846.

New vaccines containing highly conserved Streptococcus pneumoniae proteins such as pneumolysin toxoid (dPly) and histidine-triad protein D (PhtD) are being developed to provide broader protection against pneumococcal disease. This study evaluated the safety, reactogenicity and immunogenicity of different pneumococcal protein-containing formulations in adults.

Adolescent, Adult, Antibodies, Bacterial, Bacterial Proteins, Double-Blind Method, Drug-Related Side Effects and Adverse Reactions, Female, Healthy Volunteers, Humans, Hydrolases, Male, Placebos, Pneumococcal Vaccines, Streptococcus pneumoniae, Streptolysins, Vaccination, Young Adult
Adolescent, Adult, Antibodies, Bacterial, Bacterial Proteins, Double-Blind Method, Drug-Related Side Effects and Adverse Reactions, Female, Healthy Volunteers, Humans, Hydrolases, Male, Placebos, Pneumococcal Vaccines, Streptococcus pneumoniae, Streptolysins, Vaccination, Young Adult
 
Document Actions